Celecoxib for the treatment of mild‐to‐moderate depression due to acute brucellosis: a double‐blind, placebo‐controlled, randomized trial
S Jafari, SG Ashrafizadeh, A Zeinoddini… - Journal of clinical …, 2015 - Wiley Online Library
S Jafari, SG Ashrafizadeh, A Zeinoddini, M Rasoulinejad, P Entezari, S Seddighi…
Journal of clinical pharmacy and therapeutics, 2015•Wiley Online LibraryWhat is known and objective Depression is a debilitating complication of brucellosis and
how best to treat this is a matter of debate. Inflammatory processes are involved in the
pathogenesis of both brucellosis and depression. Therefore, we hypothesized that celecoxib
could be beneficial for the treatment of depression due to brucellosis. Methods Forty
outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale
score (HDRS)< 19 participated in a randomized, double‐blind, placebo‐controlled trial and …
how best to treat this is a matter of debate. Inflammatory processes are involved in the
pathogenesis of both brucellosis and depression. Therefore, we hypothesized that celecoxib
could be beneficial for the treatment of depression due to brucellosis. Methods Forty
outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale
score (HDRS)< 19 participated in a randomized, double‐blind, placebo‐controlled trial and …
What is known and objective
Depression is a debilitating complication of brucellosis and how best to treat this is a matter of debate. Inflammatory processes are involved in the pathogenesis of both brucellosis and depression. Therefore, we hypothesized that celecoxib could be beneficial for the treatment of depression due to brucellosis.
Methods
Forty outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19 participated in a randomized, double‐blind, placebo‐controlled trial and underwent 8 weeks of treatment with either celecoxib (200 mg bid) or placebo as an adjunctive to antibiotic therapy. Patients were evaluated using HDRS at baseline and weeks 4 and 8.
Result and discussion
Repeated‐measures analysis demonstrated significant effect for time × treatment interaction on the HDRS score [F (1·43, 57·41) = 37·22, P < 0·001]. Significantly greater response to treatment occurred in the celecoxib group than in the placebo group at the study end [10 patients (50%) vs. no patient (0%), respectively, P < 0·001]. No serious adverse event was observed.
What is new and conclusion
Celecoxib is a safe and effective treatment for depression due to brucellosis when compared with placebo.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果